Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030342 · ClinicalTrials.gov registry record · Phase 1
Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer
A Phase 1 study, sponsored by St. Luke's Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00030342 is a Phase 1 study that has completed, run by St. Luke's Medical Center. The registered enrollment target is 60 participants.
The verdict
NCT00030342, a Phase 1 study, has completed, sponsored by St. Luke's Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining biological therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of biological therapy combined with chemotherapy in treating patients who have metastatic kidney cancer or colorectal cancer.
Interventions
- DRUG fluorouracil
- BIOLOGICAL therapeutic autologous lymphocytes
- BIOLOGICAL recombinant interferon alfa
- BIOLOGICAL sargramostim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2001-11 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00030342
The ClinicalTrials.gov registry entry for NCT00030342 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Luke's Medical Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which fluorouracil is the first listed.
NCT00030342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00030342 about?
NCT00030342 is a clinical study titled "Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer". RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining biological therapy with chemotherapy may kill more tumor cells....
What is the current status of trial NCT00030342?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2001-11. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00030342?
The interventions under investigation include: fluorouracil (DRUG), therapeutic autologous lymphocytes (BIOLOGICAL), recombinant interferon alfa (BIOLOGICAL), sargramostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00030342?
This trial is sponsored by St. Luke's Medical Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.